European Journal of Cancer and Clinical Oncology最新文献

{"title":"Treatment of good-risk disseminated non-seminomatous germ cell tumours: the less bleomycin, the more cisplatin?","authors":"S. Culine, M. Mahjoubi, I. Philippot, J.P. Droz","doi":"10.1016/0277-5379(91)90458-P","DOIUrl":"10.1016/0277-5379(91)90458-P","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Page 1715"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90458-P","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12887729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized, parallel-group comparison of interferon alfa-2b plus hydroxyurea versus hydroxyurea alone in patients with chronic myelogenous leukaemia in chronic phase","authors":"Chong Won Park ,&nbsp;Chi Hwa Han ,&nbsp;Choon Choo Kim ,&nbsp;Dong Jip Kim","doi":"10.1016/0277-5379(91)90563-S","DOIUrl":"10.1016/0277-5379(91)90563-S","url":null,"abstract":"<div><p>A STUDY was undertaken to compare the effect of recombinant interferon alfa-2b (IFN alfa-2b) plus hydroxyurea (HU) with that of HU alone on haematological remission (HR) in patients with chronic phase chronic myelogenous leukaemia (CML). Twenty-one patients were randomized to receive either IFN alfa-2b plus HU (<em>n</em> = 12; seven male and five female; mean age 40 years, range 29–57 years) or HU alone (<em>n</em> = 9; three male and six female; mean age 35 years, range 24–50 years). All patients initially received cytoreductive therapy with HU alone, at a dose according to the white blood cell (WBC) count. When the WBC count decreased to 5−10 × 10³/μl, patients were randomized to receive either IFN alfa-2b 2 million units per day by subcutaneous (s.c.) injection plus the adjusted daily dose of HU (&gt; 150 × 10³/μl, 4g; 50−150 × 10³/μl, 3g; 30−50 × 10³/μl, 2g; 10−30 × 10³/μl, 1g; and 5−10 × 10³/μl, 0g), or HU alone. Thus, patients received no HU until their WBC count rose above 5−10 × 10³/μl. Eleven of 12 patients on IFN plus HU achieved a haematological response, including nine with complete haematological remission (CHR) (A1: <em>n</em> = 0, A2: <em>n</em> = 4, A3: <em>n</em> = 3, A4: <em>n</em> = 2) and two with partial haematological remission (PHR) (B1: <em>n</em> = 0, B2: <em>n</em> = 2), while none of the nine patients on HU alone achieved a remission with the above-mentioned doses of HU according to our criteria (A[CHR]: WBC count maintained below 9 × 10³/μl without blast and no symptoms or signs associated with CML; subclassified according to the percentage of Ph¹ chromosome: A1, Ph¹ chromosome present in all analyzable metaphases; A2, Ph¹ chromosome present in 35–59%; A3, 5–34%; A4, Ph¹ chromosome absent from all analyzable metaphases. B[PHR]: B1, reduction of peripheral WBC count by at least 50% to &lt; 20 × 10³/μl; B2, normalization of peripheral WBC count but persistence of immature form or clinically palpable splenomegaly. Failure: patients who failed to achieve a PHR or CHR as defined above). Using two sets of primer pair sequences encoding bcr-abl mRNA (A primer: 5′-GGAGCTGCAGATGCTGACCAAC-3′ encoding bcr exon II; B primer: 5′-TCAGACCCTGAGGCTCAAAGTC-3′ encoding abl exon II; A′ primer: 5′-CCTGATCTCCTCTGA CTATGAG-3′ encoding bcr exon I; B′ primer: 5′-TCCAGCGAGAAGGTTTTCCTTG-3′ encoding abl exon I), we performed the cDNA-PCR analysis, which revealed persistent bcr-abl mRNA expression in the peripheral mononuclear cells from two patients who achieved CHR induced by IFN. We suggest that IFN therapy should be continued at least until molecular remission is achieved.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S27-S28"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90563-S","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83700589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alpha interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis","authors":"Xenophon Yataganas,&nbsp;John Meletis,&nbsp;Eleni Plata,&nbsp;Nora Viniou,&nbsp;Filippos Deligiannis,&nbsp;Christina Tsekoura,&nbsp;Ersi Voscaridou,&nbsp;Viki Boussiotis,&nbsp;John Rombos,&nbsp;Georges Vayopoulos,&nbsp;Christos Kittas,&nbsp;Phaedon Fessas","doi":"10.1016/0277-5379(91)90578-2","DOIUrl":"10.1016/0277-5379(91)90578-2","url":null,"abstract":"<div><p>The effect of recombinant interferon alfa-2b on platelet count, thrombocytosis-associated symptoms and marrow fibrosis was studied in 18 patients with myeloproliferative diseases and associated thrombocytosis (nine with essential thrombocythaemia, three with polycythaemia vera, three with myelofibrosis and three with chronic myelogenous leukaemia). A reduction of the platelet count below 600 × 10⁹/L was achieved in 94%, and below 400 × 10⁹/L in 77% of the patients within 8 to 330 days of treatment. The selective thrombocytosis-reducing effect of alpha interferon was maintained for long periods of time in most patients without serious side effects. Thrombocytosis-associated symptoms were relieved once the number of platelets was reduced to near normal levels. Marrow reticulin content was found to be reduced after treatment in two of the seven patients studied. Side effects of alpha interferon were flu-like symptoms, which usually subsided within 7 days of treatment.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S69-S71"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90578-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alpha interferon in the management of essential thrombocythaemia","authors":"Manuel Giralt ,&nbsp;Daniel Rubio ,&nbsp;Ma Teresa Cortés ,&nbsp;Jesús San Miguel ,&nbsp;Juan Luis Steegmann ,&nbsp;Jesús Serena ,&nbsp;Jose Ma Fernández-Rañada ,&nbsp;Antonio López-Borrasca","doi":"10.1016/0277-5379(91)90579-3","DOIUrl":"10.1016/0277-5379(91)90579-3","url":null,"abstract":"<div><p>Thirteen patients (mean age 60.7 years; female:male ratio 10:3) with essential thrombocythaemia were treated with 3 million units (MU)/day interferon alfa-2b subcutaneously (s.c.) for 12 weeks, with all patients requiring a dose reduction after 4 weeks. The mean pretreatment platelet count was 1,400 × 10⁹/L and megakaryocytes were increased in all cases. Splenomegaly was present in six patients and haemorrhagic phenomena were observed in two. Nine patients (69.2%) had objective responses, including two (15.4%) complete responses (platelets &lt; 450 × 10⁹/L) which were then maintained with 5 MU interferon twice a week. Acute toxicity consisted of flu-like symptoms in 12 patients. Chronic toxicity (mainly leucopenia) was observed in nine patients. In conclusion, alpha interferon is a useful agent for the treatment of essential thrombocythaemia, reducing platelet count after initial therapy and then requiring maintenance therapy at a reduced dose. However, the frequent side effects observed make it advisable to use a low dose of interferon alfa-2b, and to treat only those patients with significant symptoms and signs of thrombocytosis.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S72-S74"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90579-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective review of chemotherapy for small cell lung cancer in the elderly: Does the end justify the means?","authors":"M.P.N. Findlay,&nbsp;A.-M. Griffin,&nbsp;D. Raghavan,&nbsp;K.E. McDonald,&nbsp;A.S. Coates,&nbsp;P.J. Duval,&nbsp;P. Gianoutsos","doi":"10.1016/0277-5379(91)90422-A","DOIUrl":"10.1016/0277-5379(91)90422-A","url":null,"abstract":"<div><p>Between 1978 and 1983, 72 patients aged 70 years or older (median 72, range 70–80) were treated for biopsy-proven, small cell lung cancer (SCLC). Intercurrent disorders were common, including ischaemic heart disease, peripheral vascular disease, chronic airflow limitation and second malignancies. 26 patients (36%) had limited extent of disease, and 46 (64%) had extensive disease. “Intensive” chemotherapy incorporating vincristine, cyclophosphamide and doxorubicin (OCA regimen) was administered to 32 patients [complete response (CR) + partial response (PR) = 84%]; less rigorous regimens (e.g. single agent chemotherapy, planned dose reductions, radiotherapy only) were used in 34 cases (CR + PR = 52%); and 6 received no active treatment. In the intensively treated group, there were 3 treatment-related deaths and 26 episodes of WHO grade 3–4 toxicity. In the less intensively treated group, there were no treatment-induced deaths and only 1 episode of severe toxicity. The overall median survival was 25 weeks (36 weeks for intensive treatment, 16 weeks with less intense treatment). For patients with limited disease only, the median survival in each group was 43 and 26 weeks, respectively. Intensive treatment for elderly patients with small cell lung cancer is associated with substantially increased toxicity and higher response rates than for gentle treatment, but without a major survival benefit.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1597-1601"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90422-A","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12829432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carmustine-induced toxicity, DNA crosslinking and 06-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines","authors":"Suzanne Egyházi ,&nbsp;Jonas Bergh ,&nbsp;Johan Hansson ,&nbsp;Peter Karran ,&nbsp;Ulrik Ringborg","doi":"10.1016/0277-5379(91)90440-O","DOIUrl":"10.1016/0277-5379(91)90440-O","url":null,"abstract":"<div><p>O⁶-methylguanine-DNA methyltransferase (O⁶-MT) probably plays an important role in the repair of chloroethyl-nitrosourea-induced DNA damage. O⁶-MT was studied as a possible drug resistance factor in two human lung cancer cell lines, one small cell lung cancer (U1690) and one non-small cell lung cancer (U1810), with different sensitivities to carmustine. The U1810 cell line was 3.4-fold more resistant to carmustine than U1690 cells, although the two cell lines were equally sensitive to mustine, melphalan and cisplatin. A 23-fold higher level of DNA interstrand crosslinks was observed following exposure of U1690 cells to carmustine compared with U1810 cells. The O⁶-MT activity of U1810 cells was 11 times higher than that of U1690 cells. The O⁶-MT activity in the U1810 cells showed a dose-dependent decrease after exposure to carmustine. These results show a correlation between increased O⁶-MT activity, decreased drug induced DNA interstrand crosslinking and cellular resistance to carmustine.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1658-1662"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90440-O","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12829436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer registration and incidence in Hawaii","authors":"Marc T. Goodman ,&nbsp;Grant N. Stemmermann","doi":"10.1016/0277-5379(91)90450-R","DOIUrl":"10.1016/0277-5379(91)90450-R","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1701-1706"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90450-R","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12944351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased levels of soluble interleukin-2 receptors in supernatants from peripheral blood mononuclear cells of patients with lung cancer","authors":"Pietro Marino ,&nbsp;Armando Preatoni ,&nbsp;Gianfranco Buccheri ,&nbsp;Domenico Ferrigno ,&nbsp;Adriana Fruttero","doi":"10.1016/0277-5379(91)90455-M","DOIUrl":"10.1016/0277-5379(91)90455-M","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Page 1712"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90455-M","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12944354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon","authors":"James Cassidy,&nbsp;Christopher Poole,&nbsp;Elizabeth Sharkie,&nbsp;Will P. Steward,&nbsp;Stanley B. Kaye","doi":"10.1016/0277-5379(91)90432-D","DOIUrl":"10.1016/0277-5379(91)90432-D","url":null,"abstract":"<div><p>We treated 14 patients (4 malignant melanoma/10 renal carcinoma) with a combination of continuous infusion interleukin-2 (IL-2) and subcutaneous alpha-interferon. Variable concentrations of albumin were added to the infusion of IL-2. The toxicity of this regimen seems to be related to the percentage of albumin added to the IL-2 infusion. Partial responses were observed in 3 cases. Interestingly, 1 patient's response appeared dependent on the addition of human serum albumin. The mechanism of these effects is unknown, but the use of albumin with IL-2 should be carefully investigated in future studies.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1633-1634"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90432-D","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12945230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infusion of floxuridine plus etoposide plus cisplatin in human malignancies","authors":"J. Lokich,&nbsp;C. Moore,&nbsp;N. Anderson,&nbsp;M. Bern","doi":"10.1016/0277-5379(91)90421-9","DOIUrl":"10.1016/0277-5379(91)90421-9","url":null,"abstract":"<div><p>36 patients with advanced malignancy were studied in a phase I trial of continuous 24-h infusion of floxuridine (FUdR) plus etoposide plus cisplatin (FEP) administered for 5 consecutive days at 4-week intervals. Study design fixed the dose rate of etoposide and cisplatin with escalation of FUdR only. Dose rate-limiting toxicity related to the FUdR component was stomatitis and diarrhoea and was invariably associated with leukopenia and thrombocytopenia when grade 3 or 4 level gastrointestinal toxicity was observed. Only 3 of 64 courses were associated with transient renal failure related to cisplatin. Drug-related deaths occurred (leukopenia-associated sepsis) in 4 patients with poor performance status (ECOG 3 and 4). Responses occurred in 15 of 26 evaluable patients (all previously treated minimally or untreated) including <span><math><mtext>5</mtext><mtext>11</mtext></math></span> non-small cell lung cancer; <span><math><mtext>3</mtext><mtext>3</mtext></math></span> oesophageal; <span><math><mtext>2</mtext><mtext>2</mtext></math></span> breast; <span><math><mtext>4</mtext><mtext>5</mtext></math></span> gastric; 1 osteogenic sarcoma; and 1 unknown primary (probably ovary). The recommended dose rates for a 5-day infusion of the three agents for good risk patients is 20 mg/m² per day of each drug. For poor risk patients including age &gt; 65 years; performance status 2 or greater; or extensive bone metastases or prior radiation; the recommended starting dose rates are: FUdR 15 mg/m² per day; etoposide 15 mg/m² per day; and cisplatin 20 mg/m² per day. Dose escalation of FUdR to a maximum of 25 mg/m² daily is feasible in selected patients demonstrating optimal tolerance.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1593-1596"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90421-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12998575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}